CDC Guidance

Item Date Updated
Infection Prevention
Interim US Guidance for Risk Assessment and Public Health Management of Persons with Potential COVID-19 Exposures: Geographic Risk and Contacts of Laboratory-confirmed Cases 3/7
Steps Healthcare Facilities Can Take Now to Prepare for Coronavirus Disease 2019 3/6
Strategies to Prevent the Spread of COVID-19 in Long-Term Care Facilities 3/13
Interim US Guidance for Risk Assessment and Public Health Management of Healthcare Personnel with Potential Exposure in a Healthcare Setting to Patients with COVID-19 3/7
Healthcare Infection Prevention and Control FAQs for COVID-19 4/1
Interim Infection Prevention and Control Recommendations for Patients with Confirmed COVID-19 or Persons Under Investigation for COVID-19 in Healthcare Settings 4/1
Alternative Care Sites: Guidance for critical infection prevention and control considerations for alternative care sites. 3/25
COVID-19 Outpatient Dialysis Facility Preparedness Assessment Tool: Highlights recommended areas for outpatient dialysis facilities, which hospitals should review in preparation for the potential arrivals of COVID-19 patients. 3/26
Treatment
What Healthcare Personnel Should Know about Caring for Patients with Confirmed or Possible COVID-19 Infection 3/10
Interim Clinical Guidance for Management of Patients with Confirmed 2019 Novel Coronavirus Infection 3/20
Information for Clinicians on Therapeutic Options for COVID-19 Patients: Information on three drugs currently being studied in the US to treat COVID-19; two have been FDA-approved for other purposes (chloroquine and hydroxychloroquine) and the third is an investigational agent (remdesivir) 3/21
Interim Guidance on Management of COVID-19 in Correctional and Detention Facilities 3/23
Severe Illness Associated with Using Non-Pharmaceutical Chloroquine Phosphate to Prevent and Treat COVID-19: Address cases of individuals ingesting non-pharmaceutical chloroquine phosphate, which can cause health consequences, including death. Clinicians and public health officials should discourage the public from this behavior and advise that chloroquine and the related compound hydroxychloroquine should be used only under the supervision of a health care provider as prescribed medications. 3/28
Human Infection with 2019 Novel Coronavirus Person Under Investigation (PUI) and Case Report Form
Discharge
Discontinuation of Home Isolation for Persons with COVID-19 3/16
Discontinuation of Transmission-Based Precautions and Disposition of Patients with COVID-19: clarifies that patients with COVID-19 can be discharged whenever clinically indicated, updates guidance for a test-based strategy from two swabs to one, and adds guidance for discontinuation of transmission-based precautions without testing, discontinuation of empiric transmission-based precautions for patients suspected of having COVID-19, and when a testing-based strategy for discontinuation of transmission-based precautions is preferred. 3/23

NYS DOH Guidance

Item Date Updated
COVID-19 Guidance for Hospital Operators Regarding Visitation: Effective immediately, all hospitals suspend visitation except when medically necessary (i.e., a visitor is essential to the care of the patient) or for family members or legal representatives of patients in imminent end-of-life situations 3/18
Criteria for discontinuation of quarantine of patients with COVID-19 3/19
PUI Guidance: Responding to the revised CDC criteria, DOH issued updated PUI guidance 3/6
Dear Administrator Letter: Addresses questions sent to DOH on infection control measures, health care delivery for asymptomatic persons under monitoring, and management of health care personnel with potential exposure in a health care setting 2/25
Hospital Access to Hydroxychloroquine and Azithromycin for the Treatment of COVID-19: DOH is working collaboratively with health care practitioners who are treating certain patients hospitalized with COVID-19 to implement scientific studies and research on the efficacy and tolerability of Hydroxylchloroquine and Azithromycin. This Health Advisory outlines conditions of participation in the state-approved, FDA-authorized clinical study. 3/25
COVID-19 Release from Home Isolation: Revised to follow the CDC’s non-test-based strategy 3/28

NJ DOH Guidance

NYC DOHMH Guidance

ASPR Guidance on Using CHEMPACK Assets

The US Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) has issued guidance on the use of CHEMPACK assets during the COVID-19 pandemic.

Public Health and Health Planning Council Regulations

New York State’s Public Health and Planning Council released regulations on March 10 clarifying requirements for isolation and quarantine, and updating other areas of the code applicable to local health departments and hospitals during a communicable disease outbreak.

American College of Cardiology Guidance for the Cardiovascular Care Team

The American College of Cardiology released a clinical bulletin containing COVID-19 guidance for the cardiovascular care team. The bulletin contains current COVID-19 clinical context, acute cardiac complications, implications for patients with underlying cardiovascular conditions, and cardiac-specific preparedness recommendations.

ACOG Clinical Updates

The American College of Obstetricians and Gynecologists (ACOG) has collated resources for clinicians treating pregnant COVID-19 patients. Recent updates include updated guidance on frequently asked questions around personal protective equipment (PPE) and pregnant staff members, and how to manage the second stage of labor. A recording of the March 30 joint ACOG and New York State Perinatal Quality Collaborative webinar featuring State faculty discussing treatment protocols and best practices for pregnant COVID-19 patients is available here.

CMS Updates

CMS EMTALA Requirements and Implications Related to Coronavirus Disease

The Centers for Medicare & Medicaid Services (CMS) released a memorandum on March 9 in response to inquiries from hospitals and critical access hospitals about their compliance with the Emergency Medical Treatment and Labor Act (EMTALA) in light of COVID-19. The memorandum addresses screening obligations and stabilization, transfers, and recipient hospital obligations.

CMS Addresses Spread of COVID-19

CMS issued a press release on March 4 to recommend infection control practices for all health care providers. CMS also issued guidance for inspectors on visiting facilities affected by COVID-19. CMS included links to three memoranda on the suspension of survey activities and separate hospital and nursing home guidance for infection control and prevention to mitigate COVID-19.